A federal appeals court on Wednesday said it would restrict access to a widely used abortion medication after finding that the federal government did not follow the proper process when it loosened regulations in 2016 to make the pill more easily available.

A three-judge panel of the conservative U.S. Court of Appeals for the 5th Circuit said Food and Drug Administration decisions to allow the drug mifepristone to be taken later in pregnancy, be mailed directly to patients and be prescribed by a medical professional other than a doctor were not lawful.

Despite the court’s ruling against the government and the drug manufacturer, mifepristone will remain available for now under existing regulations while the litigation continues, in accordance with a Supreme Court ruling this spring. Wednesday’s decision is likely to be appealed to the Supreme Court.

  • AutoTL;DR@lemmings.worldB
    link
    fedilink
    English
    arrow-up
    5
    arrow-down
    2
    ·
    1 year ago

    This is the best summary I could come up with:


    The legal battle over the medication has intensified since the Supreme Court overturned Roe v. Wade’s grant of a constitutional right to abortion last June, a decision that spurred multiple states to further limit or ban the procedure.

    Kacsmaryk’s mifepristone opinion embraced language used by antiabortion activists, referring to abortion providers as “abortionists” and to fetuses and embryos as “unborn humans.”

    The Justice Department, representing the FDA, and the drug manufacturer Danco Laboratories appealed Kacsmaryk’s ruling to the 5th Circuit.

    They emphasized the FDA’s reliance on dozens of studies involving thousands of patients to approve the medication, which has been used by more than 5 million women.

    Lawyers defending the drug said the antiabortion challengers had no legal right — or standing — to file the lawsuit because they were not directly harmed by the FDA’s approval of the abortion pill.

    In an initial review of Kacsmaryk’s opinion, a separate three-judge panel of the 5th Circuit declined to suspend approval of mifepristone but reversed actions taken by the FDA since 2016 to loosen restrictions on how to obtain the medication.


    I’m a bot and I’m open source!